e21129 Background: Anlotinib was approved by the National Medical Products
Administration (NMPA) on 5/8/18 and 8/30/19 for the third-line treatment of patients with …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Objective: To analyze the clinical efficacy, progression-free survival, and safety of anlotinib
in the treatment of advanced lung cancer. Methods: A retrospective analysis was conducted …

Objective Anlotinib is an oral novel multi-target tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth …

Objective: This study aimed to evaluate the treatment response, survival profiles, prognostic
factors and adverse events of anlotinib in treating advanced non-small cell lung cancer …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …

e21106 Background: Anlotinib is an oral novel receptor tyrosine kinases (RTKs) inhibitor
targeting multiple RTKs including VEGFR, PDGFR, FGFR, and c-kit. Due to its high efficacy …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Methods This study is a non-interventional, prospective, multi-center observational study of
real world cases and all registered data are collected from real clinical practice cases. Adult …

Background The aim of this study was to investigate the efficacy and safety of anlotinib for
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …